MEDI 7836Alternative Names: Anti-IL-13 MAb-YTE; MEDI7836
Latest Information Update: 12 Sep 2016
At a glance
- Originator MedImmune
- Mechanism of Action Interleukin 13 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 12 Sep 2016 Discontinued - Phase-I for Asthma (In volunteers) in United Kingdom (SC)
- 30 Apr 2016 MedImmune completes a phase I trial in Asthma (In volunteers) in the UK (NCT02388347)
- 01 Mar 2015 Phase-I clinical trials in Asthma (In volunteers) in United Kingdom (SC)